Agios Pharmaceuticals Inc Q1 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Brian and team, congrats on the progress. Brian, maybe just more on the near term, if I may. And I know there's little you and the team can perhaps say about the sickle cell readout that's upcoming. But perhaps if you could just remind us or provide some color around some of the scenarios that you are accounting for when it comes to factoring in your no-go decision. What is perhaps nested in there as you think about some of the potential outcomes of that data and how you think about the new information that's forthcoming? And also as it relates to, Brian, just the consistency of the data, as you have mentioned, you've been very pleased with that over time and how that factors into the outcome as well.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : How would you say your PAH stabilizer is different from a drug like Kuvan? And where would you see it fitting in the PKU treatment landscape with enzyme replacement and gene therapy approved or under development?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Got it. That's helpful. If I could sneak one quick one in on the sickle cell. What form will you use to announce that data? Would it be a press release or a conference? And then will you be announcing the go/no-go decision at the same time, or could there be a delay?